UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 80 filers reported holding UROGEN PHARMA LTD in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $229,470 | +334.6% | 16,379 | +221.0% | 0.00% | – |
Q2 2023 | $52,806 | +3129.7% | 5,102 | +2782.5% | 0.00% | – |
Q1 2023 | $1,635 | -85.6% | 177 | -86.2% | 0.00% | – |
Q4 2022 | $11,362 | -99.9% | 1,281 | -3.8% | 0.00% | – |
Q3 2022 | $11,074,000 | -82.2% | 1,331 | -82.4% | 0.00% | – |
Q2 2022 | $62,080,000 | +319.5% | 7,580 | +346.1% | 0.00% | – |
Q1 2022 | $14,798,000 | -65.4% | 1,699 | -62.2% | 0.00% | – |
Q4 2021 | $42,728,000 | -28.6% | 4,493 | +26.2% | 0.00% | – |
Q3 2021 | $59,862,000 | +406.5% | 3,559 | +359.8% | 0.00% | – |
Q2 2021 | $11,819,000 | -86.3% | 774 | -82.6% | 0.00% | – |
Q1 2021 | $86,472,000 | +26.9% | 4,439 | +17.4% | 0.00% | – |
Q4 2020 | $68,152,000 | -23.0% | 3,782 | -17.6% | 0.00% | – |
Q3 2020 | $88,503,000 | +217.6% | 4,588 | +330.0% | 0.00% | – |
Q2 2020 | $27,870,000 | -74.4% | 1,067 | -82.5% | 0.00% | – |
Q1 2020 | $108,788,000 | +30.8% | 6,098 | +144.6% | 0.00% | – |
Q4 2019 | $83,191,000 | +3.9% | 2,493 | -25.8% | 0.00% | – |
Q3 2019 | $80,045,000 | – | 3,359 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |